<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Epidemiology of pulmonary infections in immunocompromised patients
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Epidemiology of pulmonary infections in immunocompromised patients
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Epidemiology of pulmonary infections in immunocompromised patients
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jay A Fishman, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Emily A Blumberg, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sheila Bond, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Aug 27, 2021.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pulmonary infections are among the most common types of tissue-invasive infections in immunocompromised individuals. The spectrum of potential pathogens known to cause pulmonary infections in immunocompromised individuals has grown as a result of intensified immunosuppression, prolonged patient survival, the emergence of antimicrobial-resistant pathogens, and improved diagnostic assays. Immunocompromised hosts are defined by susceptibility to infection with organisms of little virulence in normal individuals or with increased severity of common infections. Susceptibility to specific pathogens varies based on the underlying immune defects (eg, hematopoietic stem cell transplantation, solid organ transplantation, neutropenia). All immunosuppressive treatments, including those used intermittently (eg, biologic agents targeting inflammatory mediators), should be reviewed when assessing a patient's risk for infection.
        </p>
        <p>
         Common pulmonary infections in the immunocompromised host will be reviewed here. The evaluation of an immunocompromised patient with pulmonary infiltrates is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1401.html" rel="external">
          "Approach to the immunocompromised patient with fever and pulmonary infiltrates"
         </a>
         .)
        </p>
        <p>
         Infectious risks associated with specific immunomodulating agents are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1411.html" rel="external">
          "Risk of mycobacterial infection associated with biologic agents and JAK inhibitors"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1410.html" rel="external">
          "Tumor necrosis factor-alpha inhibitors: Bacterial, viral, and fungal infections"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3939.html" rel="external">
          "Secondary immunodeficiency induced by biologic therapies"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          GENERAL CONSIDERATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pulmonary infection is the most common form of documented tissue-invasive infection observed in immunocompromised patients [
         <a href="#rid1">
          1-5
         </a>
         ]. The specific approach to management of pulmonary infection is determined by the clinical status of the patient, the type and degree of immunosuppression, and the availability of a specific microbiologic diagnosis. General considerations include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The importance of obtaining specific microbiologic diagnoses in the care of immunocompromised individuals cannot be overemphasized. Antimicrobial susceptibility testing, quantitative molecular testing, and immunohistology are essential components of the diagnostic evaluation. Newer molecular techniques (eg, broad-range polymerase chain reaction, whole-genome sequencing) are increasingly used; the clinical value of these tests remains under investigation [
         <a href="#rid6">
          6-8
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Early imaging (eg, computed tomography scan) is an important part of the diagnostic evaluation. Invasive procedures (biopsies and/or bronchoscopy) are often necessary to establish a microbiologic diagnosis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Empiric antibiotic therapy should be started as soon as possible after initial sample for cultures are obtained. Antimicrobial selection should be based on available data (eg, epidemiologic exposures, sputum Gram stain/special stain, prior microbiologic data, recent antibiotic use). Loading doses should be administered when appropriate, with subsequent adjustment for renal or hepatic dysfunction. Initial broad empiric regimens can be modified as new microbiologic data are obtained.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Reduction of the overall level of immune suppression may be a component of care. However, immune reconstitution may be detrimental with the risk of exuberant inflammatory responses, allograft rejection, and graft-versus-host disease.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Multiple simultaneous processes are common. These may include dual infection with
         <em>
          Pneumocystis jirovecii
         </em>
         (PCP; formerly
         <em>
          Pneumocystis carinii
         </em>
         ) and cytomegalovirus (CMV) or superimposition of another process (lung injury or drug toxicity). Sequential infections (eg, viral infection preceding bacterial or fungal infection) are common.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Laboratory assay results must be interpreted cautiously and must consider the clinical context of each patient. As examples, detection of galactomannan or CMV in bronchoalveolar lavage fluid do not necessarily represent invasive disease. (See
         <a class="medical medical_review" href="/z/d/html/15717.html" rel="external">
          "Diagnosis of invasive aspergillosis", section on 'Bronchoalveolar lavage fluid'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/15396.html" rel="external">
          "Clinical manifestations, diagnosis, and treatment of cytomegalovirus infection in lung transplant recipients", section on 'Clinical manifestations'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          HOST SUSCEPTIBILITY
         </span>
         <span class="headingEndMark">
          —
         </span>
         A patient's risk for infection with specific pathogens is influenced by the nature of their underlying immune defect (eg, innate or adaptive immunodeficiency). In practice, most patients have mixed immune defects.
        </p>
        <p class="headingAnchor" id="H281928278">
         <span class="h2">
          Humoral
         </span>
         <span class="headingEndMark">
          —
         </span>
         Humoral immune defects, including hypogammaglobulinemia, are common among patients with hematologic malignancies, HIV infection, nephrotic syndrome, impaired splenic function, or certain congenital disorders (eg, common variable immune deficiency) and can result from chemotherapy, biologic therapy, or chimeric antigen receptor-modified T (CAR-T) cell therapy or following organ transplantation. Among organ transplant recipients, increased attention to the role of antibody (donor-specific antibody) in allograft injury has led to increased use of plasmapheresis, proteasome or
         <a class="drug drug_general" data-topicid="8836" href="/z/d/drug information/8836.html" rel="external">
          eculizumab
         </a>
         therapies, CAR-T cell therapies, or B cell depletion with anti-CD20 therapy, all of which can induce hypogammaglobulinemia.
        </p>
        <p>
         Patients with humoral immune defects are at risk for bacteremia, sinopulmonary infections, meningitis, and skin infections caused by encapsulated bacteria (eg,
         <em>
          Streptococcus pneumoniae, Neisseria meningitidis)
         </em>
         [
         <a href="#rid9">
          9
         </a>
         ]. In addition, humoral immune defects prevent the development of fully protective antibody responses to pneumococcal vaccination, although pneumococcal infections appear to be less severe in vaccinated versus nonvaccinated immunocompromised patients [
         <a href="#rid10">
          10,11
         </a>
         ]. Patients treated with anti-CD20 antibodies are also at risk for hepatitis B virus reactivation; those treated with proteasome inhibitors have an increased risk of varicella-zoster reactivation [
         <a href="#rid12">
          12
         </a>
         ]. Whether antibody repletion offsets these defects is unclear as studies evaluating antibody repletion outside of the congenital deficiency syndromes are lacking.
        </p>
        <p class="headingAnchor" id="H3678977727">
         <span class="h2">
          Cell mediated
         </span>
         <span class="headingEndMark">
          —
         </span>
         T lymphocyte-mediated immunity is impaired in most individuals with AIDS, immunosuppression for organ transplantation, and graft-versus-host disease prophylaxis and in many with hematologic malignancies. Individuals with impaired antigen presentation by monocytes and dendritic cells may also manifest relative T cell impairment. In these individuals, infection due to intracellular organisms (eg, Mycobacteria,
         <em>
          Legionella
         </em>
         ,
         <em>
          Nocardia
         </em>
         ,
         <em>
          Strongyloides
         </em>
         ) and infection due to
         <em>
          Pneumocystis
         </em>
         , yeasts (eg,
         <em>
          Cryptococcus
         </em>
         ), dimorphic mycoses (eg,
         <em>
          Histoplasma
         </em>
         ), molds (eg,
         <em>
          Aspergillus
         </em>
         ), and herpes viruses (eg, cytomegalovirus [CMV]) are increased. CMV is also a predisposing factor in subsequent opportunistic infections (eg,
         <em>
          Pneumocystis
         </em>
         pneumonia,
         <em>
          Aspergillus
         </em>
         ). Such infections are also prominent in patients receiving ongoing T lymphocyte immunosuppressive or immunomodulatory therapies for rheumatologic diseases or inflammatory bowel disease. (See
         <a class="medical medical_review" href="/z/d/html/1396.html" rel="external">
          "Infection in the solid organ transplant recipient"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1403.html" rel="external">
          "Overview of infections following hematopoietic cell transplantation"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2195179217">
         <span class="h2">
          Neutrophils
         </span>
         <span class="headingEndMark">
          —
         </span>
         Neutropenia predisposes to infection with endogenous bacterial flora and candidemia, particularly in the presence of mucositis and indwelling intravenous catheters. Pulmonary infections due to molds,
         <em>
          Nocardia,
         </em>
         and metastatic staphylococcal infections are more common in patients with neutrophil dysfunction (chronic granulomatous disease) in addition to neutropenia and also occur in patients receiving glucocorticoids and/or T cell suppression. (See
         <a class="medical medical_review" href="/z/d/html/16708.html" rel="external">
          "Overview of neutropenic fever syndromes"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/16139.html" rel="external">
          "Diagnostic approach to the adult cancer patient with neutropenic fever"
         </a>
         .)
        </p>
        <p>
         The immunocompromised patient is also more likely to present with dissemination of pulmonary disease to the skin or central nervous system (eg,
         <em>
          Aspergillus
         </em>
         species, mycobacterial or
         <em>
          Nocardia
         </em>
         infections). When disseminated disease is being considered, careful skin examination with biopsy of concerning skin lesions, magnetic resonance imaging of the central nervous system, sampling of the cerebrospinal fluid, and bone imaging (eg, bone scan) may be helpful in diagnosis and determining response to therapy. (See
         <a class="medical medical_review" href="/z/d/html/5515.html" rel="external">
          "Nocardia infections: Epidemiology, clinical manifestations, and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8009.html" rel="external">
          "Central nervous system tuberculosis: An overview"
         </a>
         .)
        </p>
        <p>
         Genetic polymorphisms in various immune-response genes predispose to specific infections such as
         <em>
          Aspergillus
         </em>
         or CMV infections [
         <a href="#rid13">
          13,14
         </a>
         ]. Genetic mutations have also been described for some immunodeficiencies recognized in patients with recurrent infections. In general, such individuals present with chronic or recurrent bacterial, fungal, or viral infections of the skin, sinuses, respiratory, and/or gastrointestinal tract. Many develop autoimmune conditions, malignancies, atypical rashes, paucity of lymphoid tissue or lymphadenopathy, and unusual reactions or unresponsiveness to common vaccines. These disorders may affect both humoral and cellular immune functions as well as defects in innate immunity, complement, and/or phagocytosis. The evaluation of such individuals is described elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/2454.html" rel="external">
          "Epidemiology and clinical manifestations of invasive aspergillosis", section on 'Risk factors'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5949.html" rel="external">
          "Approach to the child with recurrent infections"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3908.html" rel="external">
          "Approach to the adult with recurrent infections"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h1">
          PATTERNS OF INFECTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Epidemiologic exposures combined with the patient's immune defect determine the pattern of pulmonary infection. Pulmonary infections can be divided into the following general categories:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Community acquired
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Nosocomial
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Reactivation
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Environmental exposure
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Community-acquired infection
         </span>
         <span class="headingEndMark">
          —
         </span>
         Bacterial pneumonia in the immunocompromised host most often involves the same pathogens acquired in the community by immunocompetent hosts [
         <a href="#rid7">
          7,15
         </a>
         ]. Bacterial pneumonia frequently follows a viral respiratory tract infection, infection with atypical pathogens, or cytomegalovirus [
         <a href="#rid2">
          2,16
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6990.html" rel="external">
          "Epidemiology, pathogenesis, and microbiology of community-acquired pneumonia in adults"
         </a>
         .)
        </p>
        <p>
         The potential for antimicrobial resistance in the compromised host population exceeds that in the general population, in part because of exposures to the hospital environment and to antimicrobial agents for treatment and prophylaxis and, frequently, ongoing microbial replication [
         <a href="#rid17">
          17-19
         </a>
         ]. Inadequate initial (empiric) therapy of pneumonia has been linked to increased mortality [
         <a href="#rid18">
          18
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h2">
          Hospital-acquired (nosocomial) or health care-associated infection
         </span>
         <span class="headingEndMark">
          —
         </span>
         Colonization of patients with hospital-acquired microbes occurs early in hospitalization. Hospital-acquired (nosocomial) or health care-associated pneumonias arise most commonly in patients with preexisting lung injury (eg, chronic obstructive pulmonary disease, bronchiectasis), during intubation, or following aspiration [
         <a href="#rid20">
          20
         </a>
         ]. This is common in patients who are debilitated or have hepatic or renal dysfunction, diabetes, encephalopathy, or mucositis and who may be unable to protect their airways. Lung transplant recipients with prior colonization with antimicrobial-resistant organisms, disrupted lymphatic drainage, abnormal pulmonary clearance mechanics, and immunosuppression are at particular risk. Hematogenous seeding of the lungs (septic emboli) in association with bacteremia or fungemia is common in neutropenic hosts, often in association with vascular access catheters, and may also present with skin or gastrointestinal lesions.
        </p>
        <p>
         The ESKAPE pathogens (ie,
         <em>
          Enterococcus faecium
         </em>
         ,
         <em>
          Staphylococcus aureus
         </em>
         ,
         <em>
          Klebsiella species
         </em>
         ,
         <em>
          Acinetobacter
         </em>
         spp,
         <em>
          Pseudomonas aeruginosa
         </em>
         , and
         <em>
          Enterobacter
         </em>
         spp) commonly colonize the airways, skin, intravascular catheters, endotracheal tubes, wounds, and tracheal anastomoses (in lung transplant recipients). As such, these pathogens are common causes of nosocomial pulmonary infections and are frequently multidrug resistant [
         <a href="#rid20">
          20,21
         </a>
         ]. Gram-positive organisms including streptococci resistant to fluoroquinolones used for prophylaxis and methicillin-resistant
         <em>
          S. aureus
         </em>
         may also be implicated in pneumonia in these hosts.
        </p>
        <p>
         In patients with recurrent lung infections including those with cystic fibrosis and lung and liver transplant recipients,
         <em>
          Stenotrophomonas
         </em>
         and
         <em>
          Burkholderia
         </em>
         spp
         <em>
         </em>
         as well as nontuberculous mycobacteria (NTM)
         <em>
         </em>
         may carry or develop antimicrobial resistance following exposures to multiple courses of antimicrobial therapy. Once established, such infections often require prolonged courses of bactericidal therapy and, in some cases, surgery to achieve cure [
         <a href="#rid22">
          22
         </a>
         ]. It is unclear whether these should be considered nosocomial or simply relapsed, progressively drug-resistant infections. Although NTM infection rates are low compared with other types of infection, NTM infections in transplant and other immunocompromised hosts cause significant morbidity. (See
         <a class="medical medical_review" href="/z/d/html/1413.html" rel="external">
          "Nontuberculous mycobacterial infections in solid organ transplant candidates and recipients"
         </a>
         .)
        </p>
        <p>
         Infections in lung transplant recipients are discussed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/1395.html" rel="external">
          "Bacterial infections following lung transplantation"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1394.html" rel="external">
          "Fungal infections following lung transplantation"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1407.html" rel="external">
          "Tuberculosis in solid organ transplant candidates and recipients"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1413.html" rel="external">
          "Nontuberculous mycobacterial infections in solid organ transplant candidates and recipients"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/13952.html" rel="external">
          "Viral infections following lung transplantation"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h2">
          Environmental exposures
         </span>
         <span class="headingEndMark">
          —
         </span>
         Major sources of environmental pathogens that lead to pulmonary infection in immunocompromised hosts are air, soil, and potable water. Clues to such exposures may be obtained with careful histories of patient travel (mycobacteria, parasites, endemic viruses, and fungi), home conditions (molds), occupation, and hobbies (eg, garden, farm, or animal exposures). As examples, gram-negative pneumonia (due to organisms such as
         <em>
          Legionella pneumophila
         </em>
         and
         <em>
          P. aeruginosa
         </em>
         ) occurs in patients due to a contaminated water or air supply. NTM are commonly found in water supplies.
        </p>
        <p>
         Geographically restricted infections causing significant pulmonary infection in immunocompromised hosts include endemic bacteria (eg, tuberculosis), viruses (eg, Middle East respiratory syndrome coronavirus), and fungi (eg,
         <em>
          Histoplasma
         </em>
         or
         <em>
          Coccidioides
         </em>
         spp). Exposure to soil has been linked to infections with
         <em>
          Aspergillus
         </em>
         and
         <em>
          Nocardia
         </em>
         spp and, in Southeast Asia, with
         <em>
          Penicillium marneffei
         </em>
         and
         <em>
          Burkholderia pseudomallei
         </em>
         . Caves and bird excrement carry
         <em>
          Cryptococcus neoformans. Burkholderia cepacia
         </em>
         strains from soil have been demonstrated to match clinical isolates in cystic fibrosis patients using genotyping techniques [
         <a href="#rid23">
          23
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7029.html" rel="external">
          "Microbiology, epidemiology, and pathogenesis of
          <i>
           Legionella
          </i>
          infection"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3142.html" rel="external">
          "Epidemiology, microbiology, and pathogenesis of Pseudomonas aeruginosa infection"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5344.html" rel="external">
          "Epidemiology of nontuberculous mycobacterial infections"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3033.html" rel="external">
          "Epidemiology and clinical manifestations of Talaromyces (Penicillium) marneffei infection"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2454.html" rel="external">
          "Epidemiology and clinical manifestations of invasive aspergillosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5514.html" rel="external">
          "Nocardia infections: Clinical microbiology and pathogenesis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1395.html" rel="external">
          "Bacterial infections following lung transplantation"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1395.html" rel="external">
          "Bacterial infections following lung transplantation", section on 'Burkholderia cepacia'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h2">
          Reactivation infection
         </span>
         <span class="headingEndMark">
          —
         </span>
         Latent infections may reactivate in immunocompromised hosts many years after the initial exposure. Those that can affect the lung include but are not limited to herpes viruses (eg, cytomegalovirus, varicella-zoster virus), strongyloidiasis, Chagas disease, cryptococcosis, histoplasmosis, toxoplasmosis, or mycobacterial infections. Prior to starting immunosuppressive medications, patients should be screened for pertinent latent infections. (See
         <a class="medical medical_review" href="/z/d/html/1398.html" rel="external">
          "Evaluation for infection before solid organ transplantation"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1399.html" rel="external">
          "Evaluation for infection before hematopoietic cell transplantation"
         </a>
         .)
        </p>
        <p>
         Screening for tuberculosis by
         <a class="drug drug_general" data-topicid="10029" href="/z/d/drug information/10029.html" rel="external">
          tuberculin skin test
         </a>
         or interferon-gamma release assay prior to immunosuppression is particularly important and discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/15352.html" rel="external">
          "Use of interferon-gamma release assays for diagnosis of tuberculosis infection (tuberculosis screening) in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1407.html" rel="external">
          "Tuberculosis in solid organ transplant candidates and recipients"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1411.html" rel="external">
          "Risk of mycobacterial infection associated with biologic agents and JAK inhibitors"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h1">
          PATHOGENS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The differential diagnosis of pulmonary infections in the immunocompromised host is broad. The following discussion addresses some of the most common pathogens that should be considered in the differential diagnosis.
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h2">
          Bacteria
         </span>
         <span class="headingEndMark">
          —
         </span>
         Community-acquired pathogens include
         <em>
          S. pneumoniae
         </em>
         ,
         <em>
          Haemophilus influenzae
         </em>
         ,
         <em>
          Mycoplasma
         </em>
         ,
         <em>
          Legionella
         </em>
         ,
         <em>
          Chlamydia
         </em>
         , and others. Distinction between community-acquired and nosocomial pathogens may be less meaningful as antimicrobial resistance increases [
         <a href="#rid21">
          21
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6990.html" rel="external">
          "Epidemiology, pathogenesis, and microbiology of community-acquired pneumonia in adults"
         </a>
         .)
        </p>
        <p>
         In a retrospective review of patients diagnosed with tuberculosis at Memorial Sloan-Kettering Cancer Center, patients with hematologic neoplasms and head and neck cancer had rates of tuberculosis 40 and 20 times greater than the rate among the United States population, respectively [
         <a href="#rid24">
          24
         </a>
         ]. Thus, tuberculosis must be considered in these patients with pulmonary infiltrates.
        </p>
        <p>
         The nature and time course of immunosuppression is also an important factor to consider. Acute neutropenia may provoke the rapid onset of infection due to invasive nosocomial or colonizing organisms (eg,
         <em>
          Pseudomonas
         </em>
         ,
         <em>
          Aspergillus
         </em>
         ). Successful empiric therapy generally includes agents active against organisms previously identified in the individual. (See
         <a class="medical medical_review" href="/z/d/html/1400.html" rel="external">
          "Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/13951.html" rel="external">
          "Treatment and prevention of neutropenic fever syndromes in adult cancer patients at low risk for complications"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h2">
          Fungi
         </span>
         <span class="headingEndMark">
          —
         </span>
         The three most important causes of fungal pulmonary infection are
         <em>
          Pneumocystis jirovecii
         </em>
         ,
         <em>
          Aspergillus
         </em>
         species (especially
         <em>
          A. fumigatus
         </em>
         ), and
         <em>
          C. neoformans
         </em>
         [
         <a href="#rid2">
          2,25-34
         </a>
         ]. These agents require early targeted therapy for successful outcomes.
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h3">
          Pneumocystis jirovecii
         </span>
         <span class="headingEndMark">
          —
         </span>
         <em>
          P. jirovecii
         </em>
         pneumonia is one of the most common pulmonary infections in immunocompromised patients. Risk is greatest during the first six months after organ transplantation, with prolonged neutropenia, during periods of intense immunosuppression, and with systemic glucocorticoid use [
         <a href="#rid25">
          25-28,35
         </a>
         ]. The natural reservoir of infection remains unknown. Aerosol transmission of infection has been demonstrated in animal models [
         <a href="#rid36">
          36,37
         </a>
         ]. Clusters of infections have been documented in HIV-infected patients, renal transplant recipients, and patients with hematologic malignancies; one genotyping study showed that person-to-person transmission could occur in these settings but is uncommon [
         <a href="#rid38">
          38
         </a>
         ]. Both new exposures and reactivation of undertreated prior infections remain significant factors in the incidence of disease in immunocompromised hosts. (See
         <a class="medical medical_review" href="/z/d/html/3704.html" rel="external">
          "Epidemiology, clinical presentation, and diagnosis of Pneumocystis pulmonary infection in patients with HIV"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1406.html" rel="external">
          "Epidemiology, clinical manifestations, and diagnosis of Pneumocystis pneumonia in patients without HIV"
         </a>
         .)
        </p>
        <p>
         In patients not receiving prophylaxis, the occurrence of
         <em>
          Pneumocystis
         </em>
         infection is highly associated with cytomegalovirus (CMV) infection, possibly because of the inhibitory effect of CMV on alveolar macrophages and T lymphocyte function. Risk of infection is strongly associated with immunosuppression that includes chronic glucocorticoid administration (usually 15 to 20 mg
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         equivalent daily for more than two weeks) or T lymphocyte depletion; bolus glucocorticoids and calcineurin inhibitor use contribute to the risk of infection and increased mortality. Prophylaxis against
         <em>
          Pneumocystis
         </em>
         should be administered for at-risk patients unless there are contraindications. (See
         <a class="medical medical_review" href="/z/d/html/1393.html" rel="external">
          "Treatment and prevention of Pneumocystis pneumonia in patients without HIV", section on 'Prophylaxis'
         </a>
         .)
        </p>
        <p>
         The hallmark of infection due to
         <em>
          P. jirovecii
         </em>
         is the presence of marked hypoxemia, dyspnea, and cough with a paucity of physical or radiologic findings. In transplantation and neutropenia,
         <em>
          Pneumocystis
         </em>
         pneumonia (PCP) is generally an acute or subacute infection. In lung transplant recipients, the rate of asymptomatic isolation of
         <em>
          P. jirovecii
         </em>
         approaches two-thirds of the total in some series. Of these, up to one-half are expected to develop symptomatic disease without treatment. For other immunocompromised patients without HIV infection, 5 to 12 percent of patients who are not receiving prophylaxis will develop pneumocystosis [
         <a href="#rid26">
          26
         </a>
         ]. In patients with untreated HIV, PCP is a more rapidly progressive process with a greater organism burden than in non-HIV-infected immunocompromised hosts. The risk of PCP has declined in patients with HIV infection since the advent of antiretroviral therapy.
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h3">
          Aspergillus
         </span>
         <span class="headingEndMark">
          —
         </span>
         Invasive pulmonary aspergillosis may result from primary infection acquired from a nosocomial or environmental source or may occur following immunosuppression in a patient who is chronically colonized. Infection due to non-fumigatus strains of
         <em>
          Aspergillus
         </em>
         and other molds with differing antimicrobial susceptibility patterns generally result in similar clinical presentations; hence, specific microbial diagnosis with susceptibility testing is essential for guiding therapy [
         <a href="#rid39">
          39
         </a>
         ].
        </p>
        <p>
         The risk of invasive pulmonary aspergillosis appears to be high once the respiratory tract, sinuses, or trachea are colonized and the intensity of immunosuppression is maintained or increased. Preemptive antifungal therapy may be indicated when colonization is noted, or, alternatively, prophylaxis can be given to the highest risk patients (eg, patients with acute leukemia undergoing chemotherapy and/or allogeneic hematopoietic cell transplantation [HCT] with graft-versus-host disease). The incidence of
         <em>
          Aspergillus
         </em>
         infections in HCT recipients is 3 to 14 percent [
         <a href="#rid40">
          40-42
         </a>
         ].
         <a class="drug drug_general" data-topicid="91587" href="/z/d/drug information/91587.html" rel="external">
          Ibrutinib
         </a>
         has a unique cellular target (Bruton’s tyrosine kinase in B cell malignancies) and has been associated with an excess incidence of invasive mold infection [
         <a href="#rid43">
          43
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1397.html" rel="external">
          "Prevention of infections in hematopoietic cell transplant recipients"
         </a>
         .)
        </p>
        <p>
         The clinical course is determined by the timing of recognition and treatment of infection. Necrotizing bronchopneumonia with vascular invasion is a worrisome complication, characterized by hemoptysis, hemorrhage, and/or pulmonary infarction. Extrapulmonary dissemination most often occurs in persistently neutropenic and immunosuppressed hosts. Some patients manifest extrapulmonary disease at the time of diagnosis; the brain and skin are the most common sites involved. Other molds (eg,
         <em>
          Scedosporium
         </em>
         spp, Mucorales) also cause rapidly progressive, disseminated infection but manifest different antifungal susceptibility patterns, which highlight the importance of obtaining a microbiologic diagnosis. (See
         <a class="medical medical_review" href="/z/d/html/2454.html" rel="external">
          "Epidemiology and clinical manifestations of invasive aspergillosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2459.html" rel="external">
          "Treatment and prevention of invasive aspergillosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h3">
          Cryptococcus species
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cryptococcal infection is often detected as an asymptomatic pulmonary nodule or lymph node enlargement on a routine chest radiograph. However, in one retrospective review of patients (the majority of whom were solid organ transplant recipients) with pulmonary cryptococcosis, clinical symptoms were present in 74 percent of 38 patients [
         <a href="#rid44">
          44
         </a>
         ]. The most frequent symptoms were shortness of breath, cough, and fever. The presence of a pleural effusion was a poor prognostic factor by multivariate regression analysis, and overall mortality was 24 percent. Subacute consolidation with influenza-like symptoms may occur and may progress in the immunocompromised host to acute respiratory distress syndrome. Our own clinical experience suggests that asymptomatic infection remains common [
         <a href="#rid45">
          45
         </a>
         ].
        </p>
        <p>
         The major importance of cryptococcal pulmonary infection is that the lung is the portal of entry for disseminated infection, which frequently involves the central nervous system. Presenting symptoms of the central nervous system can be subtle and nonspecific (eg, headache with or without fever). Thus, an aggressive diagnostic evaluation must be initiated even for asymptomatic pulmonary infection. Among solid organ transplant recipients, cryptococcal infection is most common in liver transplant recipients [
         <a href="#rid46">
          46
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2421.html" rel="external">
          "Cryptococcus neoformans infection outside the central nervous system"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/85842.html" rel="external">
          "Cryptococcus gattii infection: Clinical features and diagnosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h3">
          Candida species
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although
         <em>
          Candida
         </em>
         species are frequently isolated from sputum, cases of pulmonary invasion are extremely rare even in immunocompromised hosts. Thus, a positive sputum culture for
         <em>
          Candida albicans
         </em>
         should not lead to specific therapy against
         <em>
          Candida
         </em>
         spp; other processes should be sought to explain pulmonary symptoms. (See
         <a class="medical medical_review" href="/z/d/html/2436.html" rel="external">
          "Candida infections of the abdomen and thorax", section on 'Pneumonia'
         </a>
         .)
        </p>
        <p>
         By contrast, hematogenous seeding of the lungs during fungemia can occur with
         <em>
          Candida
         </em>
         species. Fungemia commonly results from infection of indwelling vascular access catheters and infection related to transplant surgery (particularly of the pancreas or liver). Other
         <em>
          Candida
         </em>
         species (eg,
         <em>
          Candida glabrata
         </em>
         and
         <em>
          Candida krusei
         </em>
         ) have become more frequent pathogens in these hosts, possibly as a result of nosocomial exposures and prior exposure to prophylactic agents including
         <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">
          fluconazole
         </a>
         .
         <em>
          C. auris
         </em>
         is an uncommon pulmonary pathogen that more frequently involves the bloodstream and is often multidrug resistant [
         <a href="#rid47">
          47
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2430.html" rel="external">
          "Management of candidemia and invasive candidiasis in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h3">
          Agents of mucormycosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Mucormycosis (previously called zygomycosis) is an infection caused by fungi that belong to the order Mucorales including Rhizopus spp, Mucor spp, Lichtheimia (previously Absidia) spp, Cunninghamella, Rhizomucor, and Apophysomyces spp [
         <a href="#rid47">
          47
         </a>
         ]. The lung is a common site of infection along with the sinuses, rhinocerebral spaces, skin, and gastrointestinal tract.
        </p>
        <p>
         Invasive disease is more common in diabetic patients often with exogenous immune suppression and neutropenia and may follow CMV infection. In the lungs, these molds cause rapidly progressive single or multiple pulmonary nodules and may produce lung infarction and necrosis, hemorrhage, and empyema. Metastatic spread to the skin is common. Surgical excision is generally required in addition to antifungal therapy. (See
         <a class="medical medical_review" href="/z/d/html/2465.html" rel="external">
          "Mucormycosis (zygomycosis)"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h3">
          Other fungi
         </span>
         <span class="headingEndMark">
          —
         </span>
         The spectrum of fungal pathogens in immunocompromised patients includes fungi with distinct antifungal susceptibility patterns. These include
         <em>
          Scedosporium apiospermum
         </em>
         complex and
         <em>
          Lomentospora prolificans
         </em>
         (formerly
         <em>
          Scedosporium prolificans
         </em>
         ),
         <em>
          Fusarium
         </em>
         spp,
         <em>
          Trichosporon
         </em>
         spp,
         <em>
          Geotrichum
         </em>
         spp, and various dematiaceous or brown-black molds. Failure to respond to therapy may suggest the need for antifungal susceptibility testing. (See
         <a class="medical medical_review" href="/z/d/html/2429.html" rel="external">
          "Treatment of Scedosporium and Lomentospora infections"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2426.html" rel="external">
          "Mycology, pathogenesis, and epidemiology of Fusarium infection"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/465.html" rel="external">
          "Antifungal susceptibility testing"
         </a>
         .)
        </p>
        <p>
         Dematiaceous molds, such as
         <em>
          Aureobasidium
         </em>
         ,
         <em>
          Alternaria
         </em>
         ,
         <em>
          Curvularia
         </em>
         ,
         <em>
          Phialophora
         </em>
         ,
         <em>
          Wangiella
         </em>
         , and
         <em>
          Cladosporium,
         </em>
         are increasingly implicated as causes of sinus, pulmonary, and central nervous system disease in transplant and leukemic patients [
         <a href="#rid48">
          48
         </a>
         ]. These filamentous organisms pose special therapeutic problems because they may be resistant to multiple antifungal agents, including amphotericin B.
        </p>
        <p class="headingAnchor" id="H19">
         <span class="h2">
          Viruses
         </span>
         <span class="headingEndMark">
          —
         </span>
         CMV is one of the most common viruses of concern in immunocompromised patients, especially transplant recipients. However, other viruses including community-acquired respiratory viruses are diagnosed commonly using either molecular screening tests or rapid antigen testing.
        </p>
        <p>
         Most pulmonary viral infections in immunocompromised patients begin insidiously with constitutional symptoms including fever and a dry, nonproductive cough; some patients develop varying degrees of tachypnea, dyspnea, and hypoxemia [
         <a href="#rid1">
          1-3
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H20">
         <span class="h3">
          Cytomegalovirus
         </span>
         <span class="headingEndMark">
          —
         </span>
         Solid organ recipients at greatest risk for primary CMV infection are donor seropositive and recipient seronegative. In contrast, the greatest risk for CMV pneumonitis following HCT occurs in the seropositive recipient of seronegative stem cells. The incidence of CMV is related to the intensity of the immunosuppressive therapy, notably T lymphocyte-depleting therapies in organ and stem cell transplantation [
         <a href="#rid49">
          49
         </a>
         ]. Much of the lung injury in the HCT recipient is due to immune responses to CMV antigens. Thus, a pneumonitis syndrome may not occur until after the reemergence of immune function with hematopoietic engraftment.
        </p>
        <p>
         In the absence of antiviral prophylaxis, CMV pneumonitis usually occurs one to four months post-solid organ transplantation [
         <a href="#rid2">
          2,50
         </a>
         ]. Late infection may occur following completion of antiviral prophylaxis or with treatment for graft rejection. The attack rate and severity of pneumonia is greater in recipients of lung allografts (approximately 50 percent) than in the other transplant groups. (See
         <a class="medical medical_review" href="/z/d/html/8313.html" rel="external">
          "Prevention of cytomegalovirus infection in lung transplant recipients"
         </a>
         .)
        </p>
        <p>
         The radiographic manifestations of CMV pneumonia can take many forms, but a bilateral, symmetrical, peribronchovascular, and alveolar process predominantly affecting the lower lobes is the most frequent. Less commonly, a focal consolidation more suggestive of a bacterial or fungal infection or even a solitary pulmonary nodule may be caused by CMV [
         <a href="#rid2">
          2
         </a>
         ]. Mixed patterns on chest radiography should suggest dual infection; CMV and PCP or
         <em>
          Aspergillus
         </em>
         are common infections that may coexist.
        </p>
        <p>
         CMV infection in transplant recipients is discussed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/15396.html" rel="external">
          "Clinical manifestations, diagnosis, and treatment of cytomegalovirus infection in lung transplant recipients"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7300.html" rel="external">
          "Clinical manifestations, diagnosis, and management of cytomegalovirus disease in kidney transplant patients"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H21">
         <span class="h3">
          Community-acquired respiratory viruses
         </span>
         <span class="headingEndMark">
          —
         </span>
         The immunocompromised patient is at increased risk for lower respiratory tract infection due to community-acquired respiratory viruses (RVI) compared with normal hosts. Influenza, parainfluenza, respiratory syncytial virus (RSV), metapneumovirus, and adenovirus infections are of special importance. Human metapneumovirus (hMPV) is an increasingly recognized pathogen of immunocompromised children and adults [
         <a href="#rid51">
          51
         </a>
         ]. In solid organ recipients, RVI may produce protracted symptoms and prolonged viral shedding with greater risk for progression from upper to lower respiratory tract infection. (See
         <a class="medical medical_review" href="/z/d/html/6990.html" rel="external">
          "Epidemiology, pathogenesis, and microbiology of community-acquired pneumonia in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7004.html" rel="external">
          "Seasonal influenza in adults: Clinical manifestations and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7009.html" rel="external">
          "Parainfluenza viruses in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8339.html" rel="external">
          "Pathogenesis, epidemiology, and clinical manifestations of adenovirus infection"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8311.html" rel="external">
          "Human metapneumovirus infections"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/13952.html" rel="external">
          "Viral infections following lung transplantation"
         </a>
         .)
        </p>
        <p>
         Coronavirus disease 2019 (COVID-19) pneumonitis is discussed separately. Immunocompromised patients admitted with COVID-19 have an increased mortality compared with normal hosts. Patients receiving assisted ventilation for COVID-19 pneumonitis, and possibly also with intensive glucocorticoid therapy, have an increased incidence of superinfection with multidrug-resistant bacteria and fungi including
         <em>
          Aspergillus
         </em>
         and the Mucorales [
         <a href="#rid52">
          52
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/128323.html" rel="external">
          "COVID-19: Clinical features"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/128404.html" rel="external">
          "COVID-19: Diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2454.html" rel="external">
          "Epidemiology and clinical manifestations of invasive aspergillosis", section on 'COVID-19-associated infection'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2465.html" rel="external">
          "Mucormycosis (zygomycosis)", section on 'Coronavirus disease 2019-associated'
         </a>
         .)
        </p>
        <p>
         The clinical history is often suggestive of the possibility of superinfection of viral pneumonitis. Marked hypoxemia or purulence of sputum may develop acutely during the course of otherwise mild upper respiratory infection. Data from retrospective studies allow some generalizations about respiratory viral infections in immunocompromised hosts.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The seasonal variability of each respiratory virus in immunocompromised hosts reflects that seen in the general community. As a result, influenza, RSV, and hMPV generally cause disease from November through April in the northern hemisphere; rhinovirus typically circulates in the fall and spring; and adenovirus and parainfluenza circulate throughout the year [
         <a href="#rid53">
          53
         </a>
         ]. Some cases may be observed earlier in immunocompromised hosts than in the general community as harbingers of an impending outbreak.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Respiratory viruses cause more severe disease with more frequent complications in immunocompromised individuals. The risk and severity of disease is greatest in individuals with significant T cell defects. The true incidence of respiratory viral infection is unknown, particularly as atypical presentations are common and may go unrecognized.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Progression from upper to lower tract disease occurs in 7 to 50 percent of HCT recipients and approximately 13 percent of solid organ transplant recipients infected with influenza [
         <a href="#rid54">
          54
         </a>
         ]. Lung recipients are at greatest risk for complications of RVI [
         <a href="#rid55">
          55
         </a>
         ]. Lower tract disease may occur in the presence of negative screening assays for respiratory viruses (eg, nasal swabs for antigen detection). (See
         <a class="medical medical_review" href="/z/d/html/7004.html" rel="external">
          "Seasonal influenza in adults: Clinical manifestations and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8311.html" rel="external">
          "Human metapneumovirus infections"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7009.html" rel="external">
          "Parainfluenza viruses in adults", section on 'Clinical manifestations'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H22">
         <span class="h3">
          Herpes simplex and varicella-zoster viruses
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients with cutaneous herpes simplex virus (HSV) and varicella-zoster virus (VZV) infections, viral dissemination to liver, lungs, brain, or gastrointestinal tract can occur in up to 10 percent of patients. Nasal, oropharyngeal, or esophageal HSV or VZV infections may spread directly to the lungs with the development of vesicular lesions in the trachea.
        </p>
        <p>
         Primary varicella pneumonia may accompany chickenpox in normal adults and in the immunocompromised host [
         <a href="#rid56">
          56
         </a>
         ]. Pulmonary involvement occurs within the first seven days of illness, with mortality approaching 18 percent [
         <a href="#rid57">
          57,58
         </a>
         ]. Chest radiographs will reveal nodular or interstitial infiltrates in up to 16 percent of adults with chickenpox, while only 10 to 25 percent of these will have clinical symptoms [
         <a href="#rid58">
          58
         </a>
         ]. Pulmonary involvement with HSV and VZV in the immunocompromised host should be considered a life-threatening emergency.
        </p>
        <p class="headingAnchor" id="H24">
         <span class="h2">
          Parasites
         </span>
         <span class="headingEndMark">
          —
         </span>
         Parasitic pathogens are not a common cause of pulmonary involvement in immunocompromised hosts. However, infection with
         <em>
          Strongyloides stercoralis
         </em>
         and
         <em>
          Toxoplasma gondii
         </em>
         are important diagnostic considerations since they can lead to life-threatening infections.
        </p>
        <p class="headingAnchor" id="H25">
         <span class="h3">
          Strongyloides
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hyperinfection strongyloidiasis is generally associated with conditions of depressed cellular immunity. Autoinfection within the gastrointestinal tract begins when rhabditiform larvae transform into filariform larvae, which penetrate the intestinal wall to enter the bloodstream, which can lead to polymicrobial bacteremia. Dissemination of filariform larvae and bacteria to the lungs, liver, heart, central nervous system, and endocrine glands induces inflammation that may result in symptomatic dysfunction of these organs. The chest radiograph reveals pulmonary infiltrates that consist of foci of hemorrhage, pneumonitis, and edema. Dual infections by CMV or PCP with
         <em>
          Strongyloides
         </em>
         may be observed. (See
         <a class="medical medical_review" href="/z/d/html/5714.html" rel="external">
          "Strongyloidiasis"
         </a>
         .)
        </p>
        <p>
         Rapid reproduction occurs in certain individuals with appropriate exposure:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients receiving glucocorticoids and calcineurin inhibitors
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Solid organ and hematopoietic cell transplant recipients
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Burn victims
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Individuals with an alcohol use disorder
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Individuals with hypogammaglobulinemia
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H26">
         <span class="h3">
          Toxoplasmosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         <em>
          T. gondii
         </em>
         pneumonia is uncommon but, when it occurs, usually represents reactivation of latent infection. Patients at risk are typically seropositive for this pathogen (40 percent of adults in the United States and over 70 percent in Europe, South America, and Africa). Over 95 percent of clinical disease is restricted to the central nervous system, but
         <em>
          T. gondii
         </em>
         can cause chorioretinitis and pneumonia. (See
         <a class="medical medical_review" href="/z/d/html/3710.html" rel="external">
          "Toxoplasmosis in patients with HIV"
         </a>
         .)
        </p>
        <p>
         Heart and lung transplant recipients who are seronegative and receive an organ from a seropositive donor appear to be a high-risk group for
         <em>
          T. gondii
         </em>
         infection, with an incidence approaching 80 percent without prophylaxis [
         <a href="#rid25">
          25
         </a>
         ]. Most infections affect only the transplanted organ including myocarditis or pneumonitis, but some cases are disseminated to the pleura and central nervous system.
        </p>
        <p class="headingAnchor" id="H53648202">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The differential diagnosis of pulmonary infections in the immunocompromised host is broad and includes bacteria, fungi, viruses, and parasites. The spectrum of potential pathogens known to cause pulmonary infections in immunocompromised individuals has grown as a result of intensified immunosuppression, prolonged patient survival, the emergence of antimicrobial-resistant pathogens, and improved diagnostic assays. (See
         <a class="local">
          'Introduction'
         </a>
         above and
         <a class="local">
          'Pathogens'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Immunocompromised hosts are defined by susceptibility to infection with organisms of little native virulence in normal individuals. Each group of hosts (eg, solid organ or hematopoietic stem cell recipients, patients with neutropenia) has enhanced susceptibility to a subset of pathogens depending upon the nature of the underlying immune defects. The risk for severe pulmonary infection should be considered a reflection of the intensity, persistence, and nature of immune deficiencies. The impact of antibody-based therapies targeting T and B lymphocytes and inflammatory mediators should be considered in the assessment of risk. (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patient exposures and the nature of the host immune defects influence the pattern of pulmonary infection. These infections can be divided into the following general categories (see
         <a class="local">
          'Patterns of infection'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Community acquired (common pathogens)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Hospital acquired (nosocomial) or health care associated
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Reactivation (latent infections, often distant from initial exposures)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Environmental exposures (patient-specific exposures)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A number of general considerations apply in the immunocompromised patient with a pulmonary infection (see
         <a class="local">
          'General considerations'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Multiple simultaneous processes are common. These may include dual infection with
         <em>
          Pneumocystis jirovecii
         </em>
         and cytomegalovirus or superimposition of another process (lung injury or drug toxicity). Sequential infections (eg, viral infection preceding bacterial or fungal infection) are also common.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Early imaging (computed tomography scan) and specific microbiologic diagnoses are essential. Invasive procedures (biopsies and bronchoscopy) are often necessary to establish a microbiologic diagnosis. Antimicrobial susceptibility testing and advanced diagnostic testing including immunohistology and molecular assays are important to the management of pneumonia in immunocompromised patient.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Microbicidal therapy must be started as soon as possible. Empiric therapy should be based upon the data that are available (epidemiologic history, sputum Gram stain, special stains, prior microbiologic data, previous courses of antimicrobial agents). Overly broad initial antimicrobial therapy can be modified based upon more specific microbiologic data as it becomes available.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Reduction of the overall level of immune suppression may be necessary to improve outcomes but can also lead to immune reconstitution syndromes.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Laboratory assay results must be interpreted cautiously and must take into account the clinical context of each patient.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4182064774">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Kieren A Marr, MD, who contributed to an earlier version of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Ettinger NA, Trulock EP. Pulmonary considerations of organ transplantation. Part I. Am Rev Respir Dis 1991; 143:1386.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fishman JA, Rubin RH. Infection in organ-transplant recipients. N Engl J Med 1998; 338:1741.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ramsey PG, Rubin RH, Tolkoff-Rubin NE, et al. The renal transplant patient with fever and pulmonary infiltrates: etiology, clinical manifestations, and management. Medicine (Baltimore) 1980; 59:206.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosenow EC 3rd. Diffuse pulmonary infiltrates in the immunocompromised host. Clin Chest Med 1990; 11:55.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Winston DJ, Emmanouilides C, Busuttil RW. Infections in liver transplant recipients. Clin Infect Dis 1995; 21:1077.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ruppé E, Baud D, Schicklin S, et al. Clinical metagenomics for the management of hospital- and healthcare-acquired pneumonia. Future Microbiol 2016; 11:427.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Di Pasquale MF, Sotgiu G, Gramegna A, et al. Prevalence and Etiology of Community-acquired Pneumonia in Immunocompromised Patients. Clin Infect Dis 2019; 68:1482.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rossen JWA, Friedrich AW, Moran-Gilad J, ESCMID Study Group for Genomic and Molecular Diagnostics (ESGMD). Practical issues in implementing whole-genome-sequencing in routine diagnostic microbiology. Clin Microbiol Infect 2018; 24:355.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Florescu DF, Kalil AC, Qiu F, et al. What is the impact of hypogammaglobulinemia on the rate of infections and survival in solid organ transplantation? A meta-analysis. Am J Transplant 2013; 13:2601.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kumar D, Rotstein C, Miyata G, et al. Randomized, double-blind, controlled trial of pneumococcal vaccination in renal transplant recipients. J Infect Dis 2003; 187:1639.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blumberg EA, Brozena SC, Stutman P, et al. Immunogenicity of pneumococcal vaccine in heart transplant recipients. Clin Infect Dis 2001; 32:307.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brioli A, Klaus M, Sayer H, et al. The risk of infections in multiple myeloma before and after the advent of novel agents: a 12-year survey. Ann Hematol 2019; 98:713.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fisher CE, Hohl TM, Fan W, et al. Validation of single nucleotide polymorphisms in invasive aspergillosis following hematopoietic cell transplantation. Blood 2017; 129:2693.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Manuel O, Pascual M, Trendelenburg M, Meylan PR. Association between mannose-binding lectin deficiency and cytomegalovirus infection after kidney transplantation. Transplantation 2007; 83:359.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Camps Serra M, Cervera C, Pumarola T, et al. Virological diagnosis in community-acquired pneumonia in immunocompromised patients. Eur Respir J 2008; 31:618.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zinter MS, Dvorak CC, Mayday MY, et al. Pulmonary Metagenomic Sequencing Suggests Missed Infections in Immunocompromised Children. Clin Infect Dis 2019; 68:1847.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Bruyn G, Whelan TP, Mulligan MS, et al. Invasive pneumococcal infections in adult lung transplant recipients. Am J Transplant 2004; 4:1366.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fernández Guerrero ML, Ramos JM, Marrero J, et al. Bacteremic pneumococcal infections in immunocompromised patients without AIDS: the impact of beta-lactam resistance on mortality. Int J Infect Dis 2003; 7:46.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Villafuerte D, Aliberti S, Soni NJ, et al. Prevalence and risk factors for Enterobacteriaceae in patients hospitalized with community-acquired pneumonia. Respirology 2020; 25:543.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171:388.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Prina E, Ranzani OT, Polverino E, et al. Risk factors associated with potentially antibiotic-resistant pathogens in community-acquired pneumonia. Ann Am Thorac Soc 2015; 12:153.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gastmeier P, Groneberg K, Weist K, Rüden H. A cluster of nosocomial Klebsiella pneumoniae bloodstream infections in a neonatal intensive care department: Identification of transmission and intervention. Am J Infect Control 2003; 31:424.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           LiPuma JJ, Spilker T, Coenye T, Gonzalez CF. An epidemic Burkholderia cepacia complex strain identified in soil. Lancet 2002; 359:2002.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kamboj M, Sepkowitz KA. The risk of tuberculosis in patients with cancer. Clin Infect Dis 2006; 42:1592.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fishman JA. Pneumocystis carinii and parasitic infections in transplantation. Infect Dis Clin North Am 1995; 9:1005.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fishman JA. Prevention of infection due to Pneumocystis carinii. Antimicrob Agents Chemother 1998; 42:995.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fishman JA. Treatment of infection due to Pneumocystis carinii. Antimicrob Agents Chemother 1998; 42:1309.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fishman JA, Roth RS, Zanzot E, et al. Use of induced sputum specimens for microbiologic diagnosis of infections due to organisms other than Pneumocystis carinii. J Clin Microbiol 1994; 32:131.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           George MJ, Snydman DR, Werner BG, et al. The independent role of cytomegalovirus as a risk factor for invasive fungal disease in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG-Study Group. Cytogam, MedImmune, Inc. Gaithersburg, Maryland. Am J Med 1997; 103:106.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hadley S, Karchmer AW. Fungal infections in solid organ transplant recipients. Infect Dis Clin North Am 1995; 9:1045.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Collins LA, Samore MH, Roberts MS, et al. Risk factors for invasive fungal infections complicating orthotopic liver transplantation. J Infect Dis 1994; 170:644.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hadley S, Samore MH, Lewis WD, et al. Major infectious complications after orthotopic liver transplantation and comparison of outcomes in patients receiving cyclosporine or FK506 as primary immunosuppression. Transplantation 1995; 59:851.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weiland D, Ferguson RM, Peterson PK, et al. Aspergillosis in 25 renal transplant patients. Epidemiology, clinical presentation, diagnosis, and management. Ann Surg 1983; 198:622.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           De La Cruz O, Silveira FP. Respiratory Fungal Infections in Solid Organ and Hematopoietic Stem Cell Transplantation. Clin Chest Med 2017; 38:727.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rodriguez M, Fishman JA. Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients. Clin Microbiol Rev 2004; 17:770.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dei-Cas E, Brun-Pascaud M, Bille-Hansen V, et al. Animal models of pneumocystosis. FEMS Immunol Med Microbiol 1998; 22:163.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wakefield AE, Stringer JR, Tamburrini E, Dei-Cas E. Genetics, metabolism and host specificity of Pneumocystis carinii. Med Mycol 1998; 36 Suppl 1:183.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Helweg-Larsen J, Tsolaki AG, Miller RF, et al. Clusters of Pneumocystis carinii pneumonia: analysis of person-to-person transmission by genotyping. QJM 1998; 91:813.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patterson TF, Thompson GR 3rd, Denning DW, et al. Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis 2016; 63:e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fukuda T, Boeckh M, Carter RA, et al. Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning. Blood 2003; 102:827.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thursky K, Byrnes G, Grigg A, et al. Risk factors for post-engraftment invasive aspergillosis in allogeneic stem cell transplantation. Bone Marrow Transplant 2004; 34:115.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marr KA, Carter RA, Crippa F, et al. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002; 34:909.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ghez D, Calleja A, Protin C, et al. Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib. Blood 2018; 131:1955.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vilchez RA, Irish W, Lacomis J, et al. The clinical epidemiology of pulmonary cryptococcosis in non-AIDS patients at a tertiary care medical center. Medicine (Baltimore) 2001; 80:308.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mueller NJ, Fishman JA. Asymptomatic pulmonary cryptococcosis in solid organ transplantation: report of four cases and review of the literature. Transpl Infect Dis 2003; 5:140.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fishman JA, Gonzalez RG, Branda JA. Case records of the Massachusetts General Hospital. Case 11-2008. A 45-year-old man with changes in mental status after liver transplantation. N Engl J Med 2008; 358:1604.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jeffery-Smith A, Taori SK, Schelenz S, et al. Candida auris: a Review of the Literature. Clin Microbiol Rev 2018; 31.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tashiro T, Nagai H, Nagaoka H, et al. Trichosporon beigelii pneumonia in patients with hematologic malignancies. Chest 1995; 108:190.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Issa NC, Fishman JA. Infectious complications of antilymphocyte therapies in solid organ transplantation. Clin Infect Dis 2009; 48:772.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med 2007; 357:2601.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Manuel O, López-Medrano F, Keiser L, et al. Influenza and other respiratory virus infections in solid organ transplant recipients. Clin Microbiol Infect 2014; 20 Suppl 7:102.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marr KA, Platt A, Tornheim JA, et al. Aspergillosis Complicating Severe Coronavirus Disease. Emerg Infect Dis 2021; 27.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ison MG, Hayden FG. Viral infections in immunocompromised patients: what's new with respiratory viruses? Curr Opin Infect Dis 2002; 15:355.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Machado CM, Boas LS, Mendes AV, et al. Low mortality rates related to respiratory virus infections after bone marrow transplantation. Bone Marrow Transplant 2003; 31:695.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peghin M, Hirsch HH, Len Ó, et al. Epidemiology and Immediate Indirect Effects of Respiratory Viruses in Lung Transplant Recipients: A 5-Year Prospective Study. Am J Transplant 2017; 17:1304.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Triebwasser JH, Harris RE, Bryant RE, Rhoades ER. Varicella pneumonia in adults. Report of seven cases and a review of literature. Medicine (Baltimore) 1967; 46:409.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Escalante CP, Rubenstein EB, Rolston KV. Outpatient antibiotic therapy for febrile episodes in low-risk neutropenic patients with cancer. Cancer Invest 1997; 15:237.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           WEBER DM, PELLECCHIA JA. VARICELLA PNEUMONIA: STUDY OF PREVALENCE IN ADULT MEN. JAMA 1965; 192:572.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 1402 Version 28.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2048827" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Pulmonary considerations of organ transplantation. Part I.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9624195" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Infection in organ-transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6997674" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : The renal transplant patient with fever and pulmonary infiltrates: etiology, clinical manifestations, and management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2182278" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Diffuse pulmonary infiltrates in the immunocompromised host.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8589125" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Infections in liver transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26934540" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Clinical metagenomics for the management of hospital- and healthcare-acquired pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31222287" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Prevalence and Etiology of Community-acquired Pneumonia in Immunocompromised Patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29117578" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Practical issues in implementing whole-genome-sequencing in routine diagnostic microbiology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23919557" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : What is the impact of hypogammaglobulinemia on the rate of infections and survival in solid organ transplantation? A meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12721944" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Randomized, double-blind, controlled trial of pneumococcal vaccination in renal transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11170924" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Immunogenicity of pneumococcal vaccine in heart transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30680505" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : The risk of infections in multiple myeloma before and after the advent of novel agents: a 12-year survey.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28270451" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Validation of single nucleotide polymorphisms in invasive aspergillosis following hematopoietic cell transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17297414" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Association between mannose-binding lectin deficiency and cytomegalovirus infection after kidney transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17959637" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Virological diagnosis in community-acquired pneumonia in immunocompromised patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30239621" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Pulmonary Metagenomic Sequencing Suggests Missed Infections in Immunocompromised Children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15268742" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Invasive pneumococcal infections in adult lung transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12718810" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Bacteremic pneumococcal infections in immunocompromised patients without AIDS: the impact of beta-lactam resistance on mortality.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31385399" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Prevalence and risk factors for Enterobacteriaceae in patients hospitalized with community-acquired pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15699079" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25521229" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Risk factors associated with potentially antibiotic-resistant pathogens in community-acquired pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14639440" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : A cluster of nosocomial Klebsiella pneumoniae bloodstream infections in a neonatal intensive care department: Identification of transmission and intervention.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12076559" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : An epidemic Burkholderia cepacia complex strain identified in soil.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16652317" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : The risk of tuberculosis in patients with cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8747777" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Pneumocystis carinii and parasitic infections in transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9593116" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Prevention of infection due to Pneumocystis carinii.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9624465" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Treatment of infection due to Pneumocystis carinii.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8126167" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Use of induced sputum specimens for microbiologic diagnosis of infections due to organisms other than Pneumocystis carinii.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9274893" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : The independent role of cytomegalovirus as a risk factor for invasive fungal disease in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG-Study Group. Cytogam, MedImmune, Inc. Gaithersburg, Maryland.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8747778" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Fungal infections in solid organ transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8077723" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Risk factors for invasive fungal infections complicating orthotopic liver transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7535482" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Major infectious complications after orthotopic liver transplantation and comparison of outcomes in patients receiving cyclosporine or FK506 as primary immunosuppression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6357114" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Aspergillosis in 25 renal transplant patients. Epidemiology, clinical presentation, diagnosis, and management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29128021" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Respiratory Fungal Infections in Solid Organ and Hematopoietic Stem Cell Transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15489347" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9792075" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Animal models of pneumocystosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9988507" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Genetics, metabolism and host specificity of Pneumocystis carinii.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10024946" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Clusters of Pneumocystis carinii pneumonia: analysis of person-to-person transmission by genotyping.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27365388" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12689933" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15156166" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Risk factors for post-engraftment invasive aspergillosis in allogeneic stem cell transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11880955" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29437588" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11552084" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : The clinical epidemiology of pulmonary cryptococcosis in non-AIDS patients at a tertiary care medical center.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14617302" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Asymptomatic pulmonary cryptococcosis in solid organ transplantation: report of four cases and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18403769" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Case records of the Massachusetts General Hospital. Case 11-2008. A 45-year-old man with changes in mental status after liver transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29142078" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Candida auris: a Review of the Literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7606957" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Trichosporon beigelii pneumonia in patients with hematologic malignancies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19207081" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Infectious complications of antilymphocyte therapies in solid organ transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18094380" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Infection in solid-organ transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26451405" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Influenza and other respiratory virus infections in solid organ transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33084566" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Aspergillosis Complicating Severe Coronavirus Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12130931" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Viral infections in immunocompromised patients: what's new with respiratory viruses?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12692610" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Low mortality rates related to respiratory virus infections after bone marrow transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27615811" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Epidemiology and Immediate Indirect Effects of Respiratory Viruses in Lung Transplant Recipients: A 5-Year Prospective Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4864340" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Varicella pneumonia in adults. Report of seven cases and a review of literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9171858" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Outpatient antibiotic therapy for febrile episodes in low-risk neutropenic patients with cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14284857" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : VARICELLA PNEUMONIA: STUDY OF PREVALENCE IN ADULT MEN.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
